Johnson & Johnson entered into a voluntary agreement with the US government to expand access to medicines and lower costs for US patients.[1] As part of the deal, J&J will offer some of its brand-name drugs at deeply discounted prices through the government-backed TrumpRx.gov platform.[1] The company will also provide drugs to state Medicaid programs at prices comparable to other developed countries.[1] The agreement is included in the framework of "most-favored-nation" (MFN) pricing and provides J&J pharmaceutical products with exemptions from US tariffs.[1] It follows J&J's previously announced plan to invest $55 billion in the US by early 2029, aimed at expanding domestic manufacturing, research, development and technology.[1] This includes the construction of two new manufacturing facilities in the US, including a cell therapy facility in Pennsylvania and a drug manufacturing facility in North Carolina, as well as the ongoing construction of a $2 billion biologics plant in Wilson, North Carolina.[1] Separately, J&J has pledged to invest $2 billion over the next 10 years in a biopharmaceutical campus in Holly Springs, North Carolina, which is expected to create about 120 jobs.[1] The announcement comes after similar agreements by the White House with several large pharmaceutical companies to lower drug prices.[1][4]